Prospera Financial Services Inc Sells 131 Shares of Cencora, Inc. (NYSE:COR)

Prospera Financial Services Inc reduced its stake in Cencora, Inc. (NYSE:COR) by 1.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,875 shares of the company’s stock after selling 131 shares during the quarter. Prospera Financial Services Inc’s holdings in Cencora were worth $2,223,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Belmont Capital LLC raised its holdings in Cencora by 91.4% in the 3rd quarter. Belmont Capital LLC now owns 88,350 shares of the company’s stock worth $19,886,000 after purchasing an additional 42,200 shares during the period. Islay Capital Management LLC raised its holdings in Cencora by 53.9% in the 3rd quarter. Islay Capital Management LLC now owns 11,861 shares of the company’s stock worth $2,670,000 after purchasing an additional 4,156 shares during the period. TrinityPoint Wealth LLC bought a new stake in Cencora during the third quarter valued at about $211,000. Thrivent Financial for Lutherans raised its holdings in Cencora by 28.5% during the third quarter. Thrivent Financial for Lutherans now owns 110,499 shares of the company’s stock valued at $24,871,000 after acquiring an additional 24,492 shares during the period. Finally, Mutual of America Capital Management LLC raised its holdings in Cencora by 2.9% during the third quarter. Mutual of America Capital Management LLC now owns 21,528 shares of the company’s stock valued at $4,846,000 after acquiring an additional 605 shares during the period. 97.52% of the stock is owned by institutional investors.

Cencora Trading Up 0.9 %

COR opened at $243.20 on Thursday. Cencora, Inc. has a 12 month low of $195.83 and a 12 month high of $251.56. The stock has a 50-day moving average of $232.82 and a 200 day moving average of $231.29. The firm has a market cap of $47.92 billion, a P/E ratio of 32.38, a P/E/G ratio of 1.60 and a beta of 0.44. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. The ex-dividend date of this dividend is Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is 29.29%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Leerink Partners decreased their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. JPMorgan Chase & Co. raised their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. UBS Group lifted their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $245.00 target price (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $271.20.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. The trade was a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.